Zarontin

(Ethosuximide)

Phase 3Small molecule

PParkedale

Zarontin is one of 125 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

124

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainActive, not recruiting

Complex Regional Pain SyndromeActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Childhood Absence EpilepsyActive, not recruiting

Irritable Bowel SyndromeActive, not recruiting

Neuropathic PainPhase 2

Active, not recruiting

Complex Regional Pain SyndromePhase 2

Active, not recruiting

Peripheral NeuropathyPhase 2

Active, not recruiting

Childhood Absence EpilepsyPhase 3

Active, not recruiting

Irritable Bowel SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

212 competitors in Neuropathic Pain

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

4 2

Namenda

AbbVie

Phase 3

3 3

Xylocaine

MMEDRx USA, Inc.

Phase 3

9 4

Briviact

UCB

Phase 3

1 5

Sativex

Jazz Pharmaceuticals

Phase 3

6 6

Ultram

WWim Janssens

Phase 3

2 7

Ketalar

Boehringer Ingelheim

Phase 3

2 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 9

Zarontin

PParkedale

Phase 3

1 10

Aspercreme Warming

AAveritas Pharma, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Irritable Bowel Syndrome

NCT04217733

Clinical

Trials by Indication[1]

Complex Regional Pain Syndrome1 trial

Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)

Terminated·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT00689585·4 enrolled

Neuropathic Pain1 trial

Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic Pain

Unknown status·UUniversity Hospital, Clermont-Ferrand·Phase 2·NCT04431778·64 enrolled

Childhood Absence Epilepsy1 trial

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

Completed·—·Phase 3·NCT00088452·453 enrolled

Peripheral Neuropathy1 trial

Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study)

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT01278004·15 enrolled

Headache1 trial

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

Terminated·UUS Department of Veterans Affairs·Phase 1/2·NCT01122381·5 enrolled

4 more indications

Treatment Resistant Depression1 trial

Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.

Completed·ZZhejiang University·Phase 1·NCT03887624·16 enrolled

Pediatrics1 trial

Population Pharmacokinetics of Antiepileptic in Pediatrics

Completed·AAssistance Publique - Hôpitaux de Paris··NCT03196466·753 enrolled

Irritable Bowel Syndrome1 trial

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Recruiting·TTanta University·Phase 3·NCT04217733·60 enrolled

IBS1 trial

Ethosuximide to Treat IBS

Unknown status·UUniversity Hospital, Clermont-Ferrand·Phase 2·NCT02973542·162 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

ZARONTIN

NDA NDA012380

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Ethosuximide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ethosuximide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ethosuximide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA012380). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Parkedale company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PParkedale

Zarontin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Complex Regional Pain Syndrome1 trial

Neuropathic Pain1 trial

Childhood Absence Epilepsy1 trial

Peripheral Neuropathy1 trial

Headache1 trial

Treatment Resistant Depression1 trial

Pediatrics1 trial

Irritable Bowel Syndrome1 trial

IBS1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News